https://news.emory.edu/tags/topic/clinical_trials/index.htmlClinical Trials news from the Emory News CenterWed, 05 Jan 2022 01:50:41 -0500https://news.emory.edu//stories/2021/12/hs_molnupiravir_eua_advisory_03-12-2021/index.htmlhttps://news.emory.edu//stories/2021/12/hs_molnupiravir_eua_advisory_03-12-2021/index.htmlA FDA panel voted in favor of a proposed Emergency Use Authorization for the antiviral drug molnupiravir.Fri, 03 Dec 2021 00:00:00 -0500https://news.emory.edu//stories/2021/11/nord_rare_diseases_genetics/index.htmlhttps://news.emory.edu//stories/2021/11/nord_rare_diseases_genetics/index.htmlThe National Organization for Rare Disorders has named Emory’s Division of Medical Genetics in the Department of Human Genetics, in partnership with the Emory Clinic and Children’s Healthcare of Atlanta, as a NORD Rare Disease Center of Excellence.Tue, 09 Nov 2021 00:00:00 -0500https://news.emory.edu//stories/2021/11/emory_joins_act_poc/index.htmlhttps://news.emory.edu//stories/2021/11/emory_joins_act_poc/index.htmlEmory University has joined forces with collaborators nationwide to form the Advancing Clinical Trials at the Point of Care (ACT@POC) Coalition to improve the quality and timeliness of evidence about the effectiveness of therapeutics. Tue, 09 Nov 2021 00:00:00 -0500https://news.emory.edu//stories/2021/09/pfizer_peds_trial_results_qanda/index.htmlhttps://news.emory.edu//stories/2021/09/pfizer_peds_trial_results_qanda/index.htmlEmory infectious disease expert Evan Anderson answers questions about what Pfizer’s initial pediatric trial results mean for children under the age of 12.Tue, 21 Sep 2021 01:00:00 -0400https://news.emory.edu//stories/2021/09/exposome_contact_tracing/index.htmlhttps://news.emory.edu//stories/2021/09/exposome_contact_tracing/index.htmlEmory researchers have developed a system for generating “xenobiotic metabolites” or breakdown products from environmental chemicals, so that they can be analyzed on a large scale. Wed, 15 Sep 2021 00:00:00 -0400https://news.emory.edu//stories/2021/08/what_full_fda_approval_of_vaccines_means/index.htmlhttps://news.emory.edu//stories/2021/08/what_full_fda_approval_of_vaccines_means/index.htmlEmory has been involved in testing all three vaccines currently in use in the U.S. Infectious disease experts Aneesh Mehta and Colleen Kelley answer questions about FDA approval, variants, masking and more.Thu, 26 Aug 2021 00:00:00 -0400https://news.emory.edu//stories/2021/08/coronavirus_emory_vaccine_study_list/index.htmlhttps://news.emory.edu//stories/2021/08/coronavirus_emory_vaccine_study_list/index.htmlEmory researchers have been involved in testing all three of the COVID-19 vaccines currently in use in the United States, along with others that may play important roles in the future.Thu, 26 Aug 2021 00:00:00 -0400https://news.emory.edu//stories/2021/08/emory_experts_on_fda_approval_of_covid_vaccines/index.htmlhttps://news.emory.edu//stories/2021/08/emory_experts_on_fda_approval_of_covid_vaccines/index.htmlThe U.S. Food and Drug Administration (FDA) has approved Pfizer-BioNTech’s COVID-19 vaccine. Emory experts are available to discuss the FDA approval announcement as well as all the other ways COVID-19 continues to impact us all. Mon, 23 Aug 2021 10:00:00 -0400https://news.emory.edu//stories/2021/08/coronavirus_baricitinib_eua/index.htmlhttps://news.emory.edu//stories/2021/08/coronavirus_baricitinib_eua/index.htmlBaricitinib, a repurposed drug that was first used against COVID-19 in the United States by Emory researchers, is emerging as a major option for treatment of hospitalized patients needing respiratory support.Tue, 10 Aug 2021 00:00:00 -0400https://news.emory.edu//stories/2021/07/coronavirus_delta_kappa_vs_vaccine_antibodies/index.htmlhttps://news.emory.edu//stories/2021/07/coronavirus_delta_kappa_vs_vaccine_antibodies/index.htmlAntibodies induced by current COVID-19 mRNA vaccines can still neutralize the Delta and Kappa variants, but at a reduced potency, according to Emory-led research.Tue, 13 Jul 2021 00:00:00 -0400